The Wall Street Journal’s Allysia Finley, member of the prominent business paper’s editorial board has gone out on the proverbial limb and aligned with Florida’s Surgeon General Joseph Ladapo who announced on March 7 that in the Sunshine State children wouldn’t need COVID-19 vaccines. In fact, that state’s Department of Health would recommend against the inoculation for healthy children.
This move created an outcry among predominantly “liberal” media declaring Dr. Ladapo’s move was reckless if not worse. Finley provides some examples such as the American Academy of Pediatrics calling the move “irresponsible” or the Infectious Diseases Society of America suggesting the doctor places politics over children’s health and safety. While Jen Psaki included her typical aggressive yet increasingly nasty as well as cursory retort telling “It’s deeply disturbing that there are politicians peddling conspiracy theories out there and casting doubt on vaccinations.”
Enter the Wall Street Journal (WSJ) author and editor in today’s opinion piece declaring that Ladapo “did no such thing” penning that Florida’s top doctor was “merely acknowledging the abundant scientific evidence that COVID-19 poses a negligible risk to healthy children, which makes it impossible to know if the benefit of vaccination outweighs the risk.”
Embrace of the Risk-Benefit Analysis?
All along TrialSite has emphasized the importance of the risk-benefit analysis for the use of these novel vaccines. On the one hand, they represent compelling new life-science-based early-stage products with enormous potential, yet they were developed in record speed and under the cover of emergency and no product liability, and with more time and scrutiny some troubling data points have emerged from safety data and the business practices of Pfizer to concerns about adverse events in some demographic cohorts.Subscribe to the Trialsitenews “COVID-19” ChannelNo spam – we promise
TrialSite has been a leader before it was politically correct to call out questionable data points associated with the development of these products. Frankly, while Trump was in office that wouldn’t have happened too often by the political right either.
TrialSite was on the record supporting Operation Warp Speed calling it a potential “game-changer” if A) development stuck to ethical and compliant good practices and B) if billions of dollars in taxpayer outlay wouldn’t be used to help companies ruthlessly monetize the pandemic while also C) the focus on economical, repurposed drugs would be included as a priority public investment target.
By the late spring of 2021 however, TrialSite started reporting on potentially troubling data points revealing possible shortcuts in the research and development lifecycle while this was one of the first media to share the biodistribution data obtained by Canadians via a Japanese Freedom of Information Act (FOIA) and later on suggested available data indicated possible trouble.
Or reporting on worrying whistleblower data involving a contract research organization overseeing three major trial sites involved with the Pfizer study. Our interview can be listened to here.
Of course, far more data has come to light thanks to the FOIA lawsuit prompted by a group of committed physicians, scientists, and lawyers targeting transparency. Much of the mainstream media forget what objective journalism meant during this pandemic—there were too many powerful financial, business, high-brow academic, and government forces at play perhaps—in America as in much of the world, money, and power can talk and everything else at times walks.
Back to Ms. Finley, she refers to evidence herself such as a Lancet study estimating that the COVID-19 infection fatality rate for the under 18 cohort equals between 0.0023% and 0.0085%—that is “2.3 to 8.5 of every 100,000 children who get infected will dies. Rates are lowest among those 5 to 11.”
Furthermore, the WSJ writer shared a CDC report that from October 3, 2020, to October 2, 2021, the total number of deaths associated with COVID-19 among children ages 5 to 11 was 66, the exact same number as died from suicide, “which is an exceedingly rare among this age group.” Furthermore, she compares the deaths for this age cohort from unintentional injury at 969 and from murder at 207.
Finley goes on with the comparisons looking into polio with 1 in 200 infected in children and a measles fatality rate of between 0.1% and 0.3% hence “why childhood vaccinations are recommended for both.”
Looking at another common virus furthermore, Finley reports for the pediatric cohort between ages 5 and 11 the hospitalization rate is 50% higher for the flu than for COVID-19 and the associated multisystem inflammatory syndrome combined.
Of course, child hospitalization has been on the rise with Omicron but as TrialSite has also indicated they remain quite low comparatively speaking—Finley writes “80% lower than among young adults.”
What about Vaccine Efficacy?
Here the WSJ author raises other concerning data points about the current early stage COVID-19 vaccine products. While the mRNA-breakthroughs represent serious potential for new therapies and vaccines over time, and they most certainly have reduced hospitalization and death rates adding value and having a place in the war against a pathogen like COVID-19—they also come with heightened safety risks, especially for young males under 40. But due to waning vaccine effectiveness (durability) starting with the Delta variant with worse performance under Omicron wholesale enforced mandates raised serious concerns about general civil liberties with an overreaching government exploiting a pandemic for its own gain.
Finley shares “The FDA authorized the emergency use authorization last October” for BNT162b2 for the 5 to 11 age cohort after one small study finding a 90% relative risk reduction effective rate yet the durability of the impact was volatile—with the vaccine’s efficacy rapidly waning. This effectiveness performance worsened with the advent of the Omicron variant.
Ms. Finley continued to refer to other studies in one case showing that “vaccinated children were more likely to catch COVID than the unvaccinated.” She suggested that natural immunity may possibly explain this away. And she reminds the WSJ reader that the CDC estimates at least 58% of children under the age of 18 “had infection-induced antibodies as of January.”
Raising the statements of recent Pfizer’s CEO toward the end of her piece, no one interested in this topic should miss Ms. Finlay’s conclusion in the WSJ. Follow the link to the piece.